Literature DB >> 9142429

Current concepts in the treatment of congestive heart failure.

J N Cohn1.   

Abstract

Heart failure is a complex syndrome; therapy should be aimed at the independent goals of prolonging life and of improving symptoms and quality of life. Some therapies are effective in achieving one goal but not the other. Short-term symptomatic relief may relate to alleviation of haemodynamic abnormalities and of congestion, whereas slowing progression of the disease and reducing mortality involve neurohormonal mechanisms, left ventricular remodelling and arrhythmia generation. Current therapy is moderately effective on these end-points, but newer approaches to management are necessary to produce more profound improvements in morbidity and mortality.

Entities:  

Mesh:

Year:  1997        PMID: 9142429     DOI: 10.1159/000177477

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  3 in total

Review 1.  Role of vasopressin antagonists in the management of acute decompensated heart failure.

Authors:  Cesare Orlandi; Christopher A Zimmer; Mihai Gheorghiade
Journal:  Curr Heart Fail Rep       Date:  2005-09

2.  The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase.

Authors:  Kobra Haghighi; Tracy Pritchard; Julie Bossuyt; Jason R Waggoner; Qunying Yuan; Guo-Chang Fan; Hanna Osinska; Ahmad Anjak; Jack Rubinstein; Jeffrey Robbins; Donald M Bers; Evangelia G Kranias
Journal:  J Mol Cell Cardiol       Date:  2011-12-01       Impact factor: 5.000

3.  Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human.

Authors:  Kobra Haghighi; Fotis Kolokathis; Luke Pater; Roy A Lynch; Michio Asahi; Anthony O Gramolini; Guo-Chang Fan; Dimitris Tsiapras; Harvey S Hahn; Stamatis Adamopoulos; Stephen B Liggett; Gerald W Dorn; David H MacLennan; Dimitrios T Kremastinos; Evangelia G Kranias
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.